Dr. Jedd Wolchok Talks About the Phase III CheckMate 067 Trial and its Effects on Untreated Melanoma Patients
Jedd D. Wolchok, MD, PhD, chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center in New York City, talks about the phase III CheckMate 067 trial.
Jedd D. Wolchok, MD, PhD, chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center in New York City, talks about the phase III CheckMate 067 trial. The trial consisted of three arms, one of which gave untreated metastatic melanoma patients ipilimumab alone, one of which treated patients with nivolumab and one of which treated patients with a combination of both, followed by nivolumab alone.
Wolchok says the study also looked at PD-L1 expression as a predictive biomarker and response rates as a secondary endpoint. He adds that the nivolumab alone arm and the combination arm shows statistically significant improvement in overall survival.
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
